SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-21-187313
Filing Date
2021-06-10
Accepted
2021-06-10 07:30:32
Documents
12
Period of Report
2021-06-07
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 5.07: Submission of Matters to a Vote of Security Holders

Document Format Files

Seq Description Document Type Size
1 8-K d101820d8k.htm   iXBRL 8-K 32964
  Complete submission text file 0001193125-21-187313.txt   157038

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA syrs-20210607.xsd EX-101.SCH 3093
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE syrs-20210607_lab.xml EX-101.LAB 18122
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE syrs-20210607_pre.xml EX-101.PRE 11420
5 EXTRACTED XBRL INSTANCE DOCUMENT d101820d8k_htm.xml XML 3353
Mailing Address 35 CAMBRIDGE PARK DRIVE CAMBRIDGE MA 02140
Business Address 35 CAMBRIDGE PARK DRIVE CAMBRIDGE MA 02140 617-744-1340
Syros Pharmaceuticals, Inc. (Filer) CIK: 0001556263 (see all company filings)

IRS No.: 453772460 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37813 | Film No.: 211006894
SIC: 2834 Pharmaceutical Preparations